PREVOZNIK MICHAEL E 4

What Happened

• Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics (DGX), had restricted stock units vest and completed related share dispositions. On 2026-02-18 he was awarded/credited with 2,013 RSUs and 9,289 underlying RSUs (total 11,302 RSUs, recorded at $0 acquisition price). To satisfy tax withholding on the vesting, 301 shares were surrendered at $210.01 ($63,213) and 347 shares at $206.99 ($71,826). Separately, on 2026-02-19 he sold 1,111 shares in the open market at $204.83 for $227,566. Total reported proceeds from dispositions: $362,605.

Key Details

• Transaction dates & prices:
  • 2026-02-18: RSU awards credited — 2,013 shares and 9,289 derivative shares (A) at $0.00.
  • 2026-02-18: Tax-withholding dispositions — 301 shares @ $210.01 ($63,213) and 347 shares @ $206.99 ($71,826) (F).
  • 2026-02-19: Open-market sale — 1,111 shares @ $204.83 ($227,566) (S).
• Shares owned after transaction: Not specified in this filing.
• Notable footnotes:
  • F1/F2: Awards are restricted stock units; some shares were surrendered to the issuer solely to cover tax withholding on RSU vesting.
  • F3: The 1,111-share sale was effected pursuant to a Rule 10b5-1 sales plan.
• Filing/timeliness: Report filed 2026-02-20 covering transactions on 2026-02-18/19; filing appears timely.

Context

• This filing reflects RSU vesting (derivative awards) and routine tax-withholding and planned selling activity rather than an outright cash purchase. The open-market sale was pre-arranged under a 10b5-1 plan, which typically indicates an automated sale schedule rather than active market timing by the insider.